Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beam Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing base-editing genetic medicines. Its Form 8-K reports cover operating results, portfolio updates, senior secured credit facility terms, license and standby license arrangements for base-editing patent rights, board changes and Regulation FD presentations.
Proxy materials describe annual meeting matters, director elections, executive compensation, equity awards and stockholder voting procedures. The filings also identify Beam’s common stock, capital structure, material agreements and governance practices tied to its clinical-stage biotechnology business.
Filing: Amendment No. 9 to Schedule 13G filed for BEAM THERAPEUTICS INC (CUSIP 07373V105) reporting a beneficial ownership position.
Key facts: FMR LLC and Abigail P. Johnson report aggregate beneficial ownership of 15,083,498.08 shares (15.0%). FMR LLC reports sole voting power of 15,073,316 and sole dispositive power of 15,083,498.08; shared powers are 0. Abigail P. Johnson reports sole dispositive power of 15,083,498.08 and no voting power. The "Date of Event Which Requires Filing" is 06/30/2025 and the signature date is 08/05/2025. Item 10 certifies the securities were not acquired to change or influence control. Exhibits referenced: Exhibit 99 (13d-1(k)(1) agreement) and Exhibit 24 (power of attorney).
Report type: Current Report on Form 8-K dated August 5, 2025 by Beam Therapeutics Inc. (BEAM).
On August 5, 2025 the Company issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into Item 2.02. The filing states that the information and Exhibit 99.1 are being furnished (not "filed") for purposes of the Exchange Act and are not subject to Section 18 liability except by specific reference.
Corporate details: Beam Therapeutics Inc., Delaware, principal office 238 Main Street, Cambridge, MA 02142; common stock trades as BEAM on Nasdaq Global Select Market. Form signed by John Evans, Chief Executive Officer.